Literature DB >> 29530945

New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.

Margaret M Centenera1,2, Luke A Selth1,3, Esmaeil Ebrahimie3, Lisa M Butler1,2, Wayne D Tilley1,3.   

Abstract

Recent genomic analyses of metastatic prostate cancer have provided important insight into adaptive changes in androgen receptor (AR) signaling that underpin resistance to androgen deprivation therapies. Novel strategies are required to circumvent these AR-mediated resistance mechanisms and thereby improve prostate cancer survival. In this review, we present a summary of AR structure and function and discuss mechanisms of AR-mediated therapy resistance that represent important areas of focus for the development of new therapies.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29530945      PMCID： PMC6280715          DOI： 10.1101/cshperspect.a030478

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN： 2157-1422            Impact factor:   6.915


  186 in total

1.  Androgen receptor decoy molecules block the growth of prostate cancer.

Authors:  Steven N Quayle; Nasrin R Mawji; Jun Wang; Marianne D Sadar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-16       Impact factor: 11.205

Review 2.  Prostate cancer.

Authors:  Gerhardt Attard; Chris Parker; Ros A Eeles; Fritz Schröder; Scott A Tomlins; Ian Tannock; Charles G Drake; Johann S de Bono
Journal:  Lancet       Date:  2015-06-11       Impact factor: 79.321

3.  Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.

Authors:  Tobias Zellweger; Kim Chi; Hideaki Miyake; Hans Adomat; Satoshi Kiyama; Kirsten Skov; Martin E Gleave
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

Review 4.  Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.

Authors:  Eric Biron; François Bédard
Journal:  J Steroid Biochem Mol Biol       Date:  2015-07-18       Impact factor: 4.292

5.  Subdomain structure of the co-chaperone SGTA and activity of its androgen receptor client.

Authors:  Andrew P Trotta; Eleanor F Need; Lisa M Butler; Luke A Selth; Melissa A O'Loughlin; Gerhard A Coetzee; Wayne D Tilley; Grant Buchanan
Journal:  J Mol Endocrinol       Date:  2012-07-25       Impact factor: 5.098

6.  Hop as an adaptor in the heat shock protein 70 (Hsp70) and hsp90 chaperone machinery.

Authors:  S Chen; D F Smith
Journal:  J Biol Chem       Date:  1998-12-25       Impact factor: 5.157

7.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

Authors:  M E Taplin; G J Bubley; T D Shuster; M E Frantz; A E Spooner; G K Ogata; H N Keer; S P Balk
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

8.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

9.  Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.

Authors:  Joanna L Gillis; Luke A Selth; Margaret M Centenera; Scott L Townley; Shihua Sun; Stephen R Plymate; Wayne D Tilley; Lisa M Butler
Journal:  Oncotarget       Date:  2013-05

10.  Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

Authors:  Mohammad Asim; Charles E Massie; Folake Orafidiya; Nelma Pértega-Gomes; Anne Y Warren; Mohsen Esmaeili; Luke A Selth; Heather I Zecchini; Katarina Luko; Arham Qureshi; Ajoeb Baridi; Suraj Menon; Basetti Madhu; Carlos Escriu; Scott Lyons; Sarah L Vowler; Vincent R Zecchini; Greg Shaw; Wiebke Hessenkemper; Roslin Russell; Hisham Mohammed; Niki Stefanos; Andy G Lynch; Elena Grigorenko; Clive D'Santos; Chris Taylor; Alastair Lamb; Rouchelle Sriranjan; Jiali Yang; Rory Stark; Scott M Dehm; Paul S Rennie; Jason S Carroll; John R Griffiths; Simon Tavaré; Ian G Mills; Iain J McEwan; Aria Baniahmad; Wayne D Tilley; David E Neal
Journal:  J Natl Cancer Inst       Date:  2015-12-11       Impact factor: 13.506
View more
  7 in total

1.  Elevated bone marrow sympathetic drive precedes systemic inflammation in angiotensin II hypertension.

Authors:  Niousha Ahmari; Monica M Santisteban; Douglas R Miller; Natalie M Geis; Riley Larkin; Ty Redler; Heather Denson; Habibeh Khoshbouei; David M Baekey; Mohan K Raizada; Jasenka Zubcevic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-31       Impact factor: 4.733

Review 2.  Prostate Organogenesis.

Authors:  Jeffrey C Francis; Amanda Swain
Journal:  Cold Spring Harb Perspect Med       Date:  2018-07-02       Impact factor: 6.915

Review 3.  Preclinical and Coclinical Studies in Prostate Cancer.

Authors:  Ming Chen; Pier Paolo Pandolfi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 4.  Heat Shock Protein 90 (HSP90) Inhibitors as Anticancer Medicines: A Review on the Computer-Aided Drug Discovery Approaches over the Past Five Years.

Authors:  Ayanda M Magwenyane; Samuel C Ugbaja; Daniel G Amoako; Anou M Somboro; Rene B Khan; Hezekiel M Kumalo
Journal:  Comput Math Methods Med       Date:  2022-05-31       Impact factor: 2.809

5.  Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis.

Authors:  Kimberley Katleba; Alan P Lombard; Maria-Malvina Tsamouri; Han Bit Baek; Kristine S Nishida; Stephen J Libertini; Alexander J Platero; Ai-Hong Ma; Chong-Xian Pan; Paramita M Ghosh; Maria Mudryj
Journal:  Cancer Lett       Date:  2021-02-04       Impact factor: 8.679

6.  A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.

Authors:  Evangelia Kounatidou; Sirintra Nakjang; Stuart R C McCracken; Scott M Dehm; Craig N Robson; Dominic Jones; Luke Gaughan
Journal:  Nucleic Acids Res       Date:  2019-06-20       Impact factor: 16.971

Review 7.  Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.

Authors:  Pravien Rajaram; Alyssa Rivera; Kevin Muthima; Nicholas Olveda; Hubert Muchalski; Qiao-Hong Chen
Journal:  Molecules       Date:  2020-05-24       Impact factor: 4.927
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.